DE60139954D1 - Immunmodulatorische konstruktionen und ihre verwendung - Google Patents

Immunmodulatorische konstruktionen und ihre verwendung

Info

Publication number
DE60139954D1
DE60139954D1 DE60139954T DE60139954T DE60139954D1 DE 60139954 D1 DE60139954 D1 DE 60139954D1 DE 60139954 T DE60139954 T DE 60139954T DE 60139954 T DE60139954 T DE 60139954T DE 60139954 D1 DE60139954 D1 DE 60139954D1
Authority
DE
Germany
Prior art keywords
immunomodulator
apc
disorder
therapeutic
prophylactic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139954T
Other languages
English (en)
Inventor
John David Fraser
Melissa Joy Nicholson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of DE60139954D1 publication Critical patent/DE60139954D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60139954T 2000-12-04 2001-12-04 Immunmodulatorische konstruktionen und ihre verwendung Expired - Lifetime DE60139954D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25124300P 2000-12-04 2000-12-04
PCT/NZ2001/000267 WO2002045739A1 (en) 2000-12-04 2001-12-04 Immunomodulatory constructs and their uses

Publications (1)

Publication Number Publication Date
DE60139954D1 true DE60139954D1 (de) 2009-10-29

Family

ID=22951085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139954T Expired - Lifetime DE60139954D1 (de) 2000-12-04 2001-12-04 Immunmodulatorische konstruktionen und ihre verwendung

Country Status (9)

Country Link
US (1) US20030124142A1 (de)
EP (1) EP1349568B1 (de)
JP (1) JP2004515479A (de)
AT (1) ATE442856T1 (de)
AU (2) AU2002216481B2 (de)
CA (1) CA2436856A1 (de)
DE (1) DE60139954D1 (de)
NZ (1) NZ544579A (de)
WO (1) WO2002045739A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
NZ519371A (en) 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
CN117679499A (zh) 2016-01-10 2024-03-12 尼奥克斯医疗有限公司 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2024077066A1 (en) * 2022-10-05 2024-04-11 Musc Foundation For Research Development Superantigen vaccine conjugate for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5519114A (en) * 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
DE19533118C1 (de) * 1995-09-07 1996-11-28 Siemens Ag Sortiereinrichtung, insbesondere für Postgut
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
AU734597B2 (en) * 1996-12-06 2001-06-21 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases

Also Published As

Publication number Publication date
CA2436856A1 (en) 2002-06-13
WO2002045739A1 (en) 2002-06-13
EP1349568A4 (de) 2005-03-30
ATE442856T1 (de) 2009-10-15
NZ544579A (en) 2007-12-21
AU1648102A (en) 2002-06-18
JP2004515479A (ja) 2004-05-27
EP1349568A1 (de) 2003-10-08
AU2002216481B2 (en) 2008-05-01
EP1349568B1 (de) 2009-09-16
US20030124142A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
DK1434603T3 (da) Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
NO20031266D0 (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
MY129263A (en) Vaccine composition
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
ATE442856T1 (de) Immunmodulatorische konstruktionen und ihre verwendung
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
NO995481L (no) Glykokonjugater av 20 (S)-camptothecin
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
MXPA04001912A (es) Aminobenzofenonas novedosas.
EP1801123A3 (de) Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
DE602004009470D1 (de) Faserreiche fraktion von trigonella-foenum-graecum-samen und verwendung davon als pharmazeutischer exzipient
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition